UroGen Pharma officer to sell 10,000 shares

URGN reports a planned Rule 144 sale by an officer of 10,000 RSU-vested ordinary shares, partly to cover tax withholding obligations.

Rhea-AI Filing Summary

UroGen Pharma Ltd. (URGN) filed a notice that officer Jason Smith may sell ordinary shares under Rule 144. The notice covers 10,000 ordinary shares, which were issued on September 8, 2026 upon vesting of RSUs, with no cash consideration. A portion of the shares is indicated as being sold to cover tax withholding obligations related to these equity awards, and Oppenheimer & Co. Inc. is listed as the broker.

Key Figures

Shares covered by Rule 144 notice: 10,000 ordinary shares Shares indicated with market value information: 1,519 ordinary shares Aggregate market value figure: $66,972.71 +1 more

4 metrics

Shares covered by Rule 144 notice 10,000 ordinary shares Shares issued upon vesting of RSUs on September 8, 2026

Shares indicated with market value information 1,519 ordinary shares Row listing 1,519 shares with related market value data

Aggregate market value figure $66,972.71 Amount shown alongside 1,519 ordinary shares in the securities information row

Date of Notice September 8, 2026 Date the Form 144 notice was signed and filed

Key Terms

Rule 144, RSUs, tax withholding obligations, equity awards

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

RSUs financial

"Shares issued upon vesting of RSUs"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

tax withholding obligations financial

"Shares sold to cover tax withholding obligations upon vesting of equity awards."

equity awards financial

"upon vesting of equity awards."

Equity awards are payments to employees or directors made in the form of company stock or rights to buy stock later, serving as a way to share ownership rather than cash. For investors, they matter because they align staff incentives with company performance, can increase the number of shares outstanding over time (which can reduce each share’s claim on profits), and create compensation costs that affect reported earnings.

FAQ

What does UroGen Pharma (URGN) disclose in this Form 144 filing?

The filing discloses that officer Jason Smith plans to sell 10,000 ordinary shares of UroGen Pharma Ltd. under Rule 144. These shares were issued upon the vesting of RSUs on September 8, 2026 and involve sales to cover tax withholding obligations.

How many UroGen Pharma (URGN) shares are covered by this Rule 144 notice?

The notice covers 10,000 ordinary shares of UroGen Pharma Ltd. The shares are tied to equity awards that vested and were issued as RSUs, with some shares being sold to satisfy related tax withholding obligations.

When were the URGN shares in this Form 144 issued and what was the consideration?

The 10,000 ordinary shares were issued on September 8, 2026 upon vesting of RSUs. The filing states there was no consideration, as the shares were issued upon vesting of RSUs rather than purchased for cash.

Why is Jason Smith selling UroGen Pharma (URGN) shares according to the filing?

The remarks section states that the shares are sold to cover tax withholding obligations upon vesting of equity awards. This indicates the sale is connected to the tax treatment of vested RSUs rather than a cash purchase of stock.

Which broker is involved in the planned URGN share sale under Rule 144?

The filing lists Oppenheimer & Co. Inc. as the broker for the ordinary shares of UroGen Pharma Ltd. covered by this Rule 144 notice. The broker is identified along with the Nasdaq market for the ordinary shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 07:35 AM Accepted by SEC EDGAR 09/09/2026 - 07:34 AM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001821479
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	UroGen Pharma Ltd.
SEC File Number	001-38079
Address of Issuer	9 HA'TA'ASIYA ST RA'ANANA, ISRAEL 4365007
Phone	972 9 770 7601
Name of Person for Whose Account the Securities are To Be Sold	Jason Smith
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary shares	Oppenheimer & Co. Inc. 85 Broad St. New York NY 10004	1519	66972.71	48721701	09/08/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary shares	09/08/2026	Shares issued upon vesting of RSUs	UroGen Pharma Ltd.			10000	09/08/2026	No consideration, shares issued upon vesting of RSUs

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	Shares sold to cover tax withholding obligations upon vesting of equity awards.
Date of Notice	09/08/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Jason Smith By: /s/ Meirav Shemesh Title: Authorized Signatory, Oppenheimer Israel (pursuant to delegation)
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)